Search results for: Biosimilars
Filter search results
The Impact of Biosimilars on Markets
24 May 2010
…provided an overview of the theoretical issues underpinning entry and pricing of biosimilars compared to chemical generics analysed examples of entry problems and regulatory hurdles associated with biosimilars discussed examples…
Biosimilars and Data Exclusivity
8 June 2010
Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of ‘traditional generics’ is a poor guide; biosimilars possess…
Price Competition and Biosimilars
23 June 2010
…greater confidence in biosimilars. Moreover, if interchangeability – or substitutability – is demonstrated for biosimilars, pharmacy benefit managers and decision makers will increase demand for lower-priced biosimilars. The comfort levels…
Biosimilars: Issues Overview
1 June 2010
…the potential for savings from the market availability of biosimilars cannot be based wholly on models derived from generic versions of small-molecule drugs. Barriers to entry for biosimilars are higher because…
Biosimilars and HTA: Results of a Roundtable Discussion
9 April 2014
…HTA to assess biosimilars, including which methods are most appropriate in specific situations. Just published is an OHE Briefing that summarises that discussion[1]. Biosimilars[2] present a range of challenges to…
Biosimilars’ Price Dynamic in Europe
30 June 2010
…biosimilars later that year – at 30% below the originator price. A price reduction by the originator was followed by further price reductions by the biosimilars and then again by one…
Estimating US Savings from Biosimilars
13 July 2010
The law signed in March 2010 eliminated some of the uncertainty about the future of biosimilars in the US. Still unclear is the impact biosimilars actually will have on costs…
EU Approval of Biosimilars
8 July 2010
…biosimilars, the differences between the biosimilar and the originator could be more important than the similarities. Immunogenicity is a particular concern with biosimilars; good data on that are essential. With respect to…
Biosimilars: Modelling the Evolution of the Market
16 June 2010
…of Prof Adrian Towse and Dr Jorge Mestre-Ferrandiz. Describing and/or forecasting the market for biosimilars must first recognize that these products are not identical, i.e., not ‘biogenerics.’ This affects both…